Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Arni Kristinsson"'
Autor:
Mark J. Caulfield, Hans Wedel, Gordon T. McInnes, Björn Dahlöf, Rory Collins, Neil R Poulter, Jesper Mehlsen, Gareth Beevers, Arni Kristinsson, Sverre E. Kjeldsen, Markku S. Nieminen, Eoin O'Brien, Peter S. Sever, Jan Östergren
AIMS: To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). METHODS AND RESULTS: The Blood Press
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1840debb0e40a2d1a4c569ea75450b9
https://doi.org/10.1093/eurheartj/ehm583
https://doi.org/10.1093/eurheartj/ehm583
Autor:
Arni Kristinsson
Publikováno v:
Acta Medica Scandinavica. 214:79-83
Programmable atrial inhibited pacemakers were implanted in two patients with orthostatic hypotension due to autonomic failure. They were paced at 95 beats/min during the day and programmed themselves to 55 beats at night. This treatment resulted in v
Autor:
Magnus Karl Petursson, Thordur Hardarson, Arni Kristinsson, Kjartan Palsson, Snorri P. Snorrason, Gudmundur Thorgeirsson
Publikováno v:
Acta Medica Scandinavica. 223:133-137
In a randomized, cross-over study 27 patients had diastolic blood pressure of greater than or equal to 96 mmHg during four visits without treatment. Following captopril 25 mg b.i.d. nine patients' blood pressure was less than or equal to 90 mmHg. The
Autor:
Peter S. Sever, S E Kjeldsen, Neil R Poulter, H Wedel, Arni Kristinsson, Markku Nieminem, Jesper Mehlsen, Jan Östergren, Gordon T. McInnes, Gareth Beevers, Eoin O'Brien, Mark J. Caulfield, Rory Collins, Björn Dahlöf
Publikováno v:
European Heart Journal. 27:2982-2988
Aims A prespecified objective of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was to assess whether any synergistic effects were apparent between the lipid-lowering and blood-pressure-lowering regimens in preventing cardiovascular events. Me
Autor:
Hans Wedel, Gareth Beevers, Rory Collins, Arni Kristinsson, Sverre E. Kjeldsen, Neil R Poulter, Björn Dahlöf, Gordon T. McInnes, Eoin O'Brien, Mark J. Caulfield, Jesper Mehlsen, Peter S. Sever, Jan Östergren, Markku S. Nieminen
Publikováno v:
Diabetes Care. 28:1151-1157
OBJECTIVE—This study aims to establish the benefits of lowering cholesterol in diabetic patients with well-controlled hypertension and average/below-average cholesterol concentrations, but without established coronary disease. RESEARCH DESIGN AND M
Autor:
Kristleifur Kristjansson, Thordur Hardarson, Jeffrey R. Gulcher, Arni Kristinsson, Sigurdur Ingason, Gudmar Thorleifsson, Kari Stefansson, Andrei Manolescu, Helga Knudsen, Augustine Kong, Michael L. Frigge
Publikováno v:
Hypertension. 39:1044-1049
We performed a genomewide scan with 904 microsatellite markers using 120 extended Icelandic families with 490 hypertensive patients. The families were identified by cross-matching a list of hypertensive patients from the Hypertension Clinic of the Un
Autor:
Hideshi Niimura, Linda L. Bachinski, Somkiat Sangwatanaroj, Hugh Watkins, Albert E. Chudley, William McKenna, Arni Kristinsson, Robert Roberts, Michael Sole, Barry J. Maron, J.G. Seidman, Christine E. Seidman, Ludwig Thierfelder, John A. Jarcho, Aris Anastasakis, Pavlos Toutouzas, Eleanor Elstein, Choong-Chin Liew, Jack Liew, John Mably, Harry Rakowski, E. Douglas Wigle, Minshun Zhao, Rosemarie Salerni, Halldora Bjornsdottir
Publikováno v:
New England Journal of Medicine. 338:1248-1257
Mutations in the gene for cardiac myosin-binding protein C account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy. The spectrum of disease-causing mutations and the associated clinical features of these gene defects are
Autor:
Arni Kristinsson, Gregory W. Albers, Knut Gjesdal, Georg Gahn, Rüdiger von Kummer, Jeanne Teitelbaum
Publikováno v:
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 35(2)
Background and Purpose:The most common stroke subtype among atrial fibrillation (AF) patients not receiving anticoagulants is cardioembolic. In the SPORTIF III and V trials, the oral direct thrombin inhibitor ximelagatran was as effective as warfarin
Autor:
Neil R Poulter, Markku S. Nieminen, Mark J. Caulfield, Hans Wedel, Peter S. Sever, Eoin O'Brien, Jan Östergren, Björn Dahlöf, Gordon T. McInnes, Jesper Mehlsen, Arni Kristinsson, Sverre E. Kjeldsen, D Gareth Beevers, Rory Collins
Publikováno v:
Lancet (London, England). 366(9489)
Background The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and β blockers used. For a given reduction in blood pressure, some suggested tha
Autor:
Björn Dahlöf, Hans Wedel, Neil R Poulter, Markku S. Nieminen, Stuart J. Pocock, Arni Kristinsson, Eoin O'Brien, Sverre E. Kjeldsen, Mark J. Caulfield, Gordon T. McInnes, Peter S. Sever, Jan Östergren, D Gareth Beevers, Jesper Mehlsen
Publikováno v:
Lancet (London, England). 366(9489)
Summary Background Results of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) show significantly lower rates of coronary and stroke events in individuals allocated an amlodipine-based combination drug regimen th